Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer

M Matthew D. Galsky (Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai) B Begoña P. Valderrama (Hospital Universitario Virgen del Rocío, Seville, Spain) M Marco Maruzzo (Istituto Oncologico Veneto (IOV)–IRCCS, Padua, Italy) A Albert Font (Catalan Institute of Oncology Badalona, Badalona Applied Research Group in Oncology, Translational Program in Cancer Research, Institut Germans Trias i Pujol, Barcelona) T Tudor Ciuleanu (Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca, Romania) J Jonathan Chatzkel (University of Florida, Gainesville) T Takuya Koie (Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan) C Christopher J. Hoimes (Duke Cancer Institute, Duke University, Durham, NC) J Javier Puente (Hospital Clínico Universitario San Carlos de Madrid, Madrid) Y Yousef Zakharia (Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA) E Eli Rosenbaum (Rabin Medical Center, Davidoff Cancer Center, Petah Tikva, Israel) K Katharina Boehm (University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany) Y Yohann Loriot (Université Paris-Saclay, Gustave Roussy, INSERM Unité Mixte de Recherche 981 — Prédicteurs Moléculaires et Nouvelles Cibles en Oncologie, Villejuif, France) J Jens Bedke (Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany) T Thomas B. Powles (Barts Health NHS Trust, Barts Cancer Institute, Queen Mary University of London, London) A Andrea Necchi (Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan Milan Italy) P Pawel Wiechno (Klinika Nowotworów Układu Moczowego, Warsaw, Poland) C Carlos Álvarez-Fernández (Hospital Universitario Central de Asturias, Oviedo, Spain) T Tae-Hwan Kim (Pohang University of Science and Technology (POSTECH) , , 77 CheongamRo , , ,) N Niara Oliveira (Mater Hospital Brisbane, Mater Misericordiae, Brisbane, QLD, Australia) T Thomas W. Flaig (University of Colorado School of Medicine, Anschutz Medical Campus, Aurora) H Heidi S. Wirtz (Pfizer, Bothell, WA) M Michael Mihm (Astellas Pharma, Northbrook, IL) Q Qinlei Huang (Merck, Rahway, NJ) A Aljosja Rogiers (Merck, Rahway, NJ) B Blanca Homet Moreno (Merck, Rahway, NJ) A Alfonso Gómez de Liaño (Complejo Hospitalario Universitario Insular–Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain)

Article Details

Volume / Issue Vol. 395, Issue 4
Published July 23, 2026
Pages 338-348
ISSN 0028-4793
Publisher Massachusetts Medical Society

Journal Info

New England Journal of Medicine

Massachusetts Medical Society

ISSN: 0028-4793 Social Sciences

Authors (27)

M

Matthew D. Galsky

Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

B

Begoña P. Valderrama

Hospital Universitario Virgen del Rocío, Seville, Spain

M

Marco Maruzzo

Istituto Oncologico Veneto (IOV)–IRCCS, Padua, Italy

A

Albert Font

Catalan Institute of Oncology Badalona, Badalona Applied Research Group in Oncology, Translational Program in Cancer Research, Institut Germans Trias i Pujol, Barcelona

T

Tudor Ciuleanu

Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca, Romania

J

Jonathan Chatzkel

University of Florida, Gainesville

T

Takuya Koie

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan

C

Christopher J. Hoimes

Duke Cancer Institute, Duke University, Durham, NC

J

Javier Puente

Hospital Clínico Universitario San Carlos de Madrid, Madrid

Y

Yousef Zakharia

Division of Hematology and Medical Oncology, Department of Internal Medicine Mayo Clinic Phoenix Arizona USA

E

Eli Rosenbaum

Rabin Medical Center, Davidoff Cancer Center, Petah Tikva, Israel

K

Katharina Boehm

University Hospital Carl Gustav Carus, Dresden University of Technology, Dresden, Germany

Y

Yohann Loriot

Université Paris-Saclay, Gustave Roussy, INSERM Unité Mixte de Recherche 981 — Prédicteurs Moléculaires et Nouvelles Cibles en Oncologie, Villejuif, France

J

Jens Bedke

Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany

T

Thomas B. Powles

Barts Health NHS Trust, Barts Cancer Institute, Queen Mary University of London, London

A

Andrea Necchi

Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori University of Milan Milan Italy

P

Pawel Wiechno

Klinika Nowotworów Układu Moczowego, Warsaw, Poland

C

Carlos Álvarez-Fernández

Hospital Universitario Central de Asturias, Oviedo, Spain

T

Tae-Hwan Kim

Pohang University of Science and Technology (POSTECH) , , 77 CheongamRo , , ,

N

Niara Oliveira

Mater Hospital Brisbane, Mater Misericordiae, Brisbane, QLD, Australia

T

Thomas W. Flaig

University of Colorado School of Medicine, Anschutz Medical Campus, Aurora

H

Heidi S. Wirtz

Pfizer, Bothell, WA

M

Michael Mihm

Astellas Pharma, Northbrook, IL

Q

Qinlei Huang

Merck, Rahway, NJ

A

Aljosja Rogiers

Merck, Rahway, NJ

B

Blanca Homet Moreno

Merck, Rahway, NJ

A

Alfonso Gómez de Liaño

Complejo Hospitalario Universitario Insular–Materno Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain